

NATIONAL NEUROSCIENCE INSTITUTE



National
Neuroscience Institute
SingHealth

Senior Management:

Professor Lee Wei Ling, Director

Current Headcount:

303 (Singapore)

Company Background

The National Neuroscience Institute (NNI) was established in 1999 as the national and regional centre of excellence for treatment, education and research in the neurosciences. It provides clinical neuroscience services to local hospitals, coordinates and provides neuroscience training and conducts basic and clinical neuroscience research in Singapore.

Services & Capabilities

NNI's Neurology department has been involved in numerous industry-sponsored and investigator-initiated clinical studies. These studies involve patients with conditions such as ischemic stroke, Parkinson's disease, epilepsy and dementia. The Neurosurgery department has also worked on pharmaceutical company-sponsored and academic Phase 2 and Phase 3 drug trials, as well as medical device studies. These trials mostly involve patients with traumatic brain injuries, subarachnoid haemorrhage, brain tumour and other diseases requiring neurosurgical intervention.

Further Information

NNI is seeking strategic partners for research collaboration. For further information please contact NNI at nni_secretariat@nni.com.sg or visit its website (www.nni.com.sg).

NUHS INVESTIGATIONAL MEDICINE UNIT

NUHS

National University
Health System

Senior Management:

Associate Professor Goh Boon Cher, Director

Dr Gerard Wong, Deputy Director

Current Headcount:

19 (Singapore)

Company Background

The NUHS Investigational Medicine Unit (IMU) was set up in 2008 as a key node that integrates ongoing research programmes with upcoming ones in experimental therapeutics and investigational medicine that are being developed at the NUS Yong Loo Lin School of Medicine and the National University Hospital. It has also worked with major pharmaceutical companies, supporting their clinical development activities in Singapore and the region.

Services & Capabilities

The IMU carries out GCP-compliant studies, focusing on early research in humans, including Proof of Concept, Phase 1 and Phase 2a trials for novel drugs and diagnostics. It also hosts various studies like First-in-Man trials, research in biomarkers and disease mechanisms as well as bio-imaging analysis.

The IMU has a fully-equipped clinical research facility as well as core facilities comprising the Cardiovascular Imaging Core Laboratory, the Pharmacokinetics and Pharmacodynamics Analytical Lab and the Genomics Core Lab. Researchers can tap upon these facilities and also gain access to scientific expertise provided by clinician-investigators, clinical pharmacologists, biostatisticians and other support staff of the IMU.

Further Information

For further information please contact the IMU at +65 6772 5080 or visit its website (http://www.nuhs.edu.sg/html/pagetree/view_5054.html).

SINGAPORE CLINICAL RESEARCH INSTITUTE PTE LTD



Senior Management:

Dr A. John Rush, CEO

Current Headcount:

54 (Singapore)

Company Background

The Singapore Clinical Research Institute (SCRI) was established in 2008, to strengthen Singapore's clinical research capacity. It was formed from the Clinical Trials and Epidemiology Research Unit (CTERU), which was set up in 1996. The SCRI supports the development, design, execution, analysis, scientific publication and public dissemination of clinical research that evaluates new potential therapeutic options and ways to deliver or target treatments.

The SCRI is interested in the scientific development of Singapore and provides collaboration and support needed for focused and effective clinical research at sites in Singapore and beyond. It offers assistance to clients in critical areas like protocol development and enhancement, research operations, research informatics and site development.

Services & Capabilities

The SCRI and its predecessor, the CTERU, has been involved in the conduct of over 25 clinical trials and other research studies, including a number of international multi-centre clinical trials. Biomedical sciences companies can tap upon the institute's clinical research expertise in areas such as study design, statistical analysis and reporting, systematic reviews, medical writing, project management, study monitoring and data management.

Further Information

The SCRI is actively seeking strategic partnerships with biomedical sciences companies. For further information please contact Dr Sam Lim at sam.lim@scri.edu.sg or visit the SCRI website (www.scri.edu.sg).

SINGHEALTH INVESTIGATIONAL MEDICINE UNIT



Senior Management:

Professor Fong Kok Yong,
Acting Executive Director, IMU
Dr Darren Lim,
Deputy Director, IMU

Current Headcount:

14 (Singapore)

Company Background

The Singhealth IMU is a 30 bedded early-phase clinical research facility set up in 2009. The IMU provides facilities to conduct early phase (Phase 1 and Phase 2a) human medical research in novel drugs, devices, biologics and diagnostics. SingHealth IMU takes part in educational activities, aimed at promoting medical research practice and methodology.

Services & Capabilities

Research activities at the IMU include various types of studies such as microdosing (Phase-0) studies, Proof of Mechanism (POM) studies, Phase 1 studies (e.g. First-in-Man, pharmacokinetic, pharmacodynamic, Proof-of-Principle, etc) and Phase 2a studies (e.g. Proof-of-Concept).

The SingHealth IMU is equipped with state of the art 2-bedded chronobiology laboratory. It has the subject matter expertise to both advance the science of chronotherapeutics and provides drug makers with the capability to study and enhance the chronotherapeutic properties of their compounds.

Further Information

For more information please contact Ms Sue Tee at sue.tee@singhealth.com.sg or visit the IMU's website (<http://research.singhealth.com.sg/Research/IMU/Pages/Default.aspx>).